Whalesbook
Reliance's Jio Platforms achieves a global top 20 patent ranking, JSW Energy expands its power portfolio with a major acquisition, and HPCL announces a significant final dividend. Meanwhile, Dr Reddy's enters the US oncology market with a first-to-market generic launch, and Hitachi Energy invests Rs 2,000 crore in a new manufacturing facility.
Reliance Jio's Innovation Milestone
Jio Platforms, the digital and technology arm of Reliance Industries, has reached a significant global milestone by entering the top 20 of the World Intellectual Property Organization's (WIPO) Patent Cooperation Treaty rankings. The company climbed 320 positions in 2025, becoming the only Indian technology innovator in the elite list. This rise reflects Jio's focus on deep-tech areas including 5G, 6G, Artificial Intelligence, and cloud-native platforms. For investors, this highlights the company's aggressive shift toward owning core technology and infrastructure, moving beyond being a mere service provider.
JSW Energy's Thermal Expansion
JSW Energy has signed a deal to acquire 100% of Maruti Clean Coal and Power for approximately Rs 1,410 crore. This acquisition includes a 300 MW operational thermal power plant in Korba, Chhattisgarh. The move is part of JSW Energy's strategy to reach 30 GW of power generation capacity by 2030. The asset comes with a long-term Power Purchase Agreement (PPA) with Rajasthan discoms, which provides revenue stability. The acquisition is intended to strengthen the company’s thermal portfolio and improve cash flow visibility.
Hitachi Energy's Manufacturing Push
Hitachi Energy India is investing roughly Rs 2,000 crore to establish a new Large Power Transformer factory in Vadodara, Gujarat. Scheduled for completion by FY28, this facility is designed to support the rising demand for electricity and grid modernization. As India pushes to integrate more renewable energy, the demand for reliable power transmission equipment like transformers is rising. The project is expected to create over 1,000 jobs and aligns with the company's commitment to the 'Make in India' initiative.
HPCL Declares Final Dividend
Hindustan Petroleum Corporation Limited (HPCL) has recommended a final dividend of Rs 19.25 per share for the financial year 2026. This is the company's highest final dividend in five years, reflecting strong financial performance in the recently concluded fiscal year. The record date for eligibility is August 14, 2026. Investors should note that dividend payouts are subject to shareholder approval at the upcoming Annual General Meeting.
Dr Reddy's Oncology Launch
Dr Reddy's Laboratories has launched the first generic version of Bosutinib Tablets (400 mg) in the United States. This product, developed in collaboration with MSN Laboratories, is a treatment for chronic myeloid leukemia. By being the first-to-market generic, the company has secured 180 days of market exclusivity, which typically helps in capturing a larger market share before other generic competitors enter. This launch is a key move for the company to bolster its US oncology portfolio.
Nestle India and Quality Allegations
Nestle India has publicly denied recent allegations regarding infestation in Maggi noodles, which had previously caused some market concern and a decline in share price. The company stated that it has conducted its own quality analysis on batch and market samples, and an independent laboratory report confirmed that the products comply with all safety standards and are free of any infestation. Nestle has submitted these findings to the Food Safety and Standards Authority of India (FSSAI). Investors may track how this situation is resolved with regulators to gauge any potential impact on brand perception or business operations.
What Investors Should Track
For Reliance, the focus remains on the commercialization of its AI and 5G intellectual property. For JSW Energy, the monitorable is the successful integration of the newly acquired plant. Hitachi Energy's project execution timeline will be key, given the large capital spending. For HPCL, future dividend trends will depend on sustained refining margins. Dr Reddy's will be monitored for the sustainability of its US market share for new launches, while Nestle India’s resolution of regulatory queries will be the primary concern for shareholders in the near term.